Stocktoria
MUSTANG BIO, INC. MBIO
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2017-08-22
MUSTANG BIO, INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating income | -$2.4M | -$16.2M | -$49.3M | -$76.2M | -$66.7M |
| Income tax | $27,000 | — | — | — | — |
| Net income | -$1.9M | -$15.8M | -$51.6M | -$77.5M | -$66.4M |
| EPS (diluted) | $-0.39 | $-38.57 | $-299.95 | $-10.09 | $-0.76 |
| Operating cash flow | -$5.3M | -$11.4M | -$49.5M | -$65.1M | -$53.7M |
| Free cash flow | — | -$11.4M | -$49.5M | -$67.8M | -$57.7M |
| Cash & equivalents | $17.3M | $6.8M | $6.2M | $75.7M | $109.6M |
| Total assets | $17.6M | $9.3M | $17.7M | $92.4M | $125.2M |
| Total liabilities | $8.1M | $13.2M | $17.6M | $46.1M | $12.8M |
| Shareholders' equity | $9.5M | -$3.9M | $123,000 | $46.3M | $112.4M |
Source: SEC EDGAR filings · CIK 0001680048 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.